Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: Systematic review and economic evaluation

Health Technology Assessment

Volumn 21, Issue 2, 2017, Pages 1-217

  Johnston, Rhona ^a   Uthman, Olalekan ^b   Cummins, Ewen ^a   Clar, Christine ^c   Royle, Pamela ^b   Colquitt, Jill ^d   Tan, Bee Kang ^b   Clegg, Andrew ^e   Shantikumar, Saran ^b   Court, Rachel ^b   O’Hare, J Paul ^b   McGrane, David ^f   Holt, Tim ^g   Waugh, Norman ^b  

^a McMDC   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c Effective Evidence ^*  (Germany)

^d EFFECTIVE EVIDENCE LLP   (United Kingdom)

^e UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^f QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ECONOMIC EVALUATION; GLYCEMIC CONTROL; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SYSTEMATIC REVIEW; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; BODY MASS; COST BENEFIT ANALYSIS; DOSE RESPONSE; ECONOMICS; GLUCOSE BLOOD LEVEL; META ANALYSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CANAGLIFLOZIN; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, ECONOMETRIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85011850203     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta21020     Document Type: Article

References (295)

1. Public Health England. Diabetes Prevalence Model (APHO). 2014. URL: www.yhpho.org.uk/resource/view.aspx?RID=81090 (accessed 4 September 2015).
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012;29:855-62. https://doi.org/10.1111/j.1464-5491.2012.03698.x
3. Health and Social Care Information Centre. Prescribing for Diabetes: England 2005-06 to 2013-14. 2014. URL: www.hscic.gov.uk/catalogue/PUB14681/pres-diab-eng-200506-201314-rep. pdf (accessed 4 September 2014).
4. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58. https://doi.org/10.2337/diab.44.11.1249
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12. https://doi.org/10.1001/jama.281.21.2005
6. Hippisley-Cox J, Pringle M. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet 2004;364:423-8. http://dx.doi.org/10.1016/S0140-6736(04)16765-2
7. Thomsen RW, Baggesen LM, Søgaard M, Pedersen L, Nørrelund H, Buhl ES, et al. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes. Diabetologia 2015;58:2247-53. http://dx.doi.org/10.1007/s00125-015-3698-1
8. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes: The Management of Type 2 Diabetes. NICE guidelines [CG87]. 2009. URL: www.nice.org.uk/guidance/cg87 (accessed September 2015).
9. National Institute for Health and Care Excellence (NICE). Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes. NICE technology appraisal guidance [TA288]. 2013. URL: www.nice.org.uk/guidance/ta288 (accessed 29 September 2015).
10. National Institute for Health and Care Excellence (NICE). Canagliflozin in Combination Therapy for Treating Type 2 Diabetes. NICE technology appraisal guidance [TA315]. 2014. URL: www.nice.org.uk/guidance/ta315 (accessed 29 September 2015).
11. National Institute for Health and Care Excellence (NICE). Empagliflozin in Combination Therapy for Treating Type 2 Diabetes. NICE technology appraisal guidance [TA336]. 2015. URL: www.nice.org.uk/guidance/ta336 (accessed 29 September 2015).
12. European Medicines Agency (EMA). Trulicity (dulaglutide): Summary of Product Characteristics. 2014. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdf (accessed 29 July 2015).
13. European Medicines Agency (EMA). Eperzan (albiglutide): Summary of Product Characteristics. 2014. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002735/WC500165117.pdf (accessed 29 September 2015).
14. Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:e001986. http://dx.doi.org/10.1136/bmjopen-2012-001986
15. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;2:CD004654. https://doi.org/10.1002/14651858.cd004654.pub2
16. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management. NG28, December 2015. URL: www.nice.org.uk/guidance/ng28 (accessed January 2016).
17. Satoh J, Takahashi K, Takizawa Y, Ishihara H, Hirai M, Katagiri H, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract 2005;70:291-7. http://dx.doi.org/10.1016/j.diabres.2005.04.002
18. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80. https://doi.org/10.2337/diacare.26.4.1176
19. Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014;30:11-22. http://dx.doi.org/10.1002/dmrr.2470
20. Monami M, Dicembrini I, Kundisova L, Zannoni S, Nreu B, Mannucci E. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab 2014;16:833-40. http://dx.doi.org/10.1111/dom.12287
21. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42. http://dx.doi.org/10.1111/j.1365-2362.2004.01381.x
22. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28. http://dx.doi.org/10.1056/NEJMoa1203858
23. Zoungas S, Chalmers J, Kengne AP, Pillai A, Billot L, de Galan B, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract 2010;89:126-33. http://dx.doi.org/10.1016/j.diabres.2010.05.012
24. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7. https://doi.org/10.1007/s00125-007-0599-y
25. Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. PLOS ONE 2014;9:e82880. http://dx.doi.org/10.1371/journal.pone.0082880
26. Schrijnders D, Houweling ST, Landman GW. Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on! Diabetes Care 2015;38:170-5. https://doi.org/10.2337/dc15-0293
27. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015;3:43-51. http://dx.doi.org/10.1016/S2213-8587(14)70213-X
28. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900-8. http://dx.doi.org/10.1093/eurheartj/ehr077
29. Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes. Guideline no. 116. 2010. URL: www.sign.ac.uk/guidelines/fulltext/116/index.html (accessed 4 September 2015).
30. American Diabetes Association (ADA). (7) Approaches to glycemic treatment. Diabetes Care 2015;38(Suppl 1):41-8. https://doi.org/10.2337/dc15-S010
31. Drouin P. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study. J Diabetes Complicat 2000;14:185-91. https://doi.org/10.1016/S1056-8727(00)00086-6
32. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105-13. https://doi.org/10.1016/S2213-8587(14)70219-0
33. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med 2012;172:1005-11. https://doi.org/10.1001/archinternmed.2012.1938
34. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK General Practice Research Database. BMJ 2009;339:b4731. http://dx.doi.org/10.1136/bmj.b4731
35. Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 2012;55:2929-37. http://dx.doi.org/10.1007/s00125-012-2668-0
36. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344:e3645. http://dx.doi.org/10.1136/bmj.e3645
37. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55:1953-62. http://dx.doi.org/10.1007/s00125-012-2538-9
38. Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015;314:265-77. http://dx.doi.org/10.1001/jama.2015.7996
39. Ryder RE. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabet Med 2015;32:305-13. http://dx.doi.org/10.1111/dme.12627
40. Gale EA. Pioglitazone: are rumours of its death exaggerated? Diabet Med 2015;32:431-7. http://dx.doi.org/10.1111/dme.12708
41. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015;58:493-504. http://dx.doi.org/10.1007/s00125-014-3456-9
42. Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer 2013;13:310. http://dx.doi.org/10.1186/1471-2407-13-310
43. European Medicines Agency (EMA). European Medicines Agency Clarifies Opinion on Pioglitazone and the Risk of Bladder Cancer; 2011. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/10/news_detail_001368.jsp&mid=WC0b01ac058004d5c1 (accessed 4 September 2015).
44. Medicines and Healthcare products Regulatory Agency (MHRA). Pioglitazone: Risk of bladder Cancer. 2011. URL: www.gov.uk/drug-safety-update/pioglitazone-risk-of-bladder-cancer (accessed 4 September 2015).
45. Craig J, Bradbury I, Cummins E, Downie S, Foster L, Stout A. The Use of B-type Natriuretic Peptides (BNP and NT-proBNP) in the Investigation of Patients with Suspected Heart Failure. Health Technology Assessment Report 6, Health Technology Board for Scotland. 2005. URL: www.healthcareimprovementscotland.org/previous_resources/hta_report/hta_6.aspx (accessed 9 September 2015).
46. Hansen L, Ekstrom CT, Tabanera YPR, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006;91:3446-50. https://doi.org/10.1210/jc.2006-0590
47. Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 2011;15(38). http://dx.doi.org/10.3310/hta15380
48. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-82. https://doi.org/10.1097/01.ASN.0000092790.89332.D2
49. Hanefeld M, Forst T. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet 2010;375:2196-8. http://dx.doi.org/10.1016/S0140-6736(10)60749-0
50. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6. http://dx.doi.org/10.1038/clpt.2008.251
51. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61:2199-204. http://dx.doi.org/10.2337/db12-0052
52. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-19. http://dx.doi.org/10.1038/clpt.2008.250
53. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61. http://dx.doi.org/10.2337/dc12-2391
54. Stein P, Berg JK, Morrow L, Polidori D, Artis E, Rusch S, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metab Clin Exp 2014;63:1296-303. http://dx.doi.org/10.1016/j.metabol.2014.07.003
55. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodiumglucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014;8:262-75.e9. http://dx.doi.org/10.1016/j.jash.2014.01.007
56. NHS Business Services Authority. Electronic Drug Tariff. 2015. URL: www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx (accessed 4 September 2015).
57. National Institute for Health and Care Excellence (NICE). Canagliflozin, Dapagliflozin and Empagliflozin monotherapy for Treating Type 2 Diabetes. Final Scope. 2015. URL: www.nice.org. uk/guidance/TA390/documents/diabetes-type-2-canagliflozin-dapagliflozin-and-empagliflozinmonotherapy-id756-final-scope2 (accessed April 2015).
58. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9. http://dx.doi.org/10.1056/NEJM199602293340906
59. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7. https://doi.org/10.1016/S0002-9343(97)00254-4
60. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9. http://dx.doi.org/10.1056/NEJM199508313330902
61. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20:565-72. http://dx.doi.org/10.1185/030079904125003278
62. Scarpello JH. Improving survival with metformin: the evidence base today. Diabetes Metab 2003;29:6S36-43.
63. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 1998;15:651-6. http://dx.doi.org/10.1002/(SICI)1096-9136(199808)15:8%3C651::AID-DIA628%3E3.0.CO;2-A
64. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD, DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with Type 2 diabetes: a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8. https://doi.org/10.1046/j.1464-5491.2001.00509.x
65. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;4:CD002967. http://dx.doi.org/10.1002/14651858.CD002967.pub4
66. Okayasu S, Kitaichi K, Hori A, Suwa T, Horikawa Y, Yamamoto M, et al. The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. Biol Pharm Bull 2012;35:933-7. https://doi.org/10.1248/bpb.35.933
67. American Diabetes Association (ADA). (6) Glycemic targets. Diabetes Care 2015;38(Suppl 1):33-40. https://doi.org/10.2337/dc15-S009
68. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:d6898. http://dx.doi.org/10.1136/bmj.d6898
69. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. https://doi.org/10.1016/S0140-6736(98)07019-6
70. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89. http://dx.doi.org/10.1056/NEJMoa0806470
71. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. http://dx.doi.org/10.1056/NEJMoa0802743
72. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. http://dx.doi.org/10.1056/NEJMoa0802987
73. Boussageon R, Bejan-Angoulvan T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169. https://doi.org/10.1136/bmj.d4169
74. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 2014;174:1227-34. http://dx.doi.org/10.1001/jamainternmed.2014.2894
75. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. 2011. URL: http://handbook.cochrane.org/(accessed 24 September 2105).
76. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother 2014;15:1501-15. http://dx.doi.org/10.1517/14656566.2014.935764
77. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24. http://dx.doi.org/10.2337/dc10-0612
78. Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebocontrolled 102-week trial. Diabet Med 2015;32:531-41. http://dx.doi.org/10.1111/dme.12624
79. Ji L, Ma J, Li H, Mansfield TA, T’joen CL, Iqbal N, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 2014;36:84-100.e9. http://dx.doi.org/10.1016/j.clinthera.2013.11.002
80. Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, Langkilde AM. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab 2014;16:1102-10. http://dx.doi.org/10.1111/dom.12325
81. Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015;38:394-402. [Erratum published in Diabetes Care 2015;38:1173]. http://dx.doi.org/10.2337/dc14-2365
82. Roden M, Weng J, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin (EMPA) monotherapy for >76 weeks in drug-naive patients with type 2 diabetes (type 2 diabetes). Diabetes 2014;63(Suppl.):A69.
83. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC, EMPA-REGMONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1:208-19. http://dx.doi.org/10.1016/S2213-8587(13)70084-6
84. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82. http://dx.doi.org/10.1111/dom.12054
85. Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with SGLT2 inhibition. Diabetes Obes Metab 2016;18:125-34. https://doi.org/10.1111/dom.12578
86. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy Balance after sodiumglucose cotransporter 2 inhibition. Diabetes Care 2015;38:1730-5. http://dx.doi.org/10.2337/dc15-0355
87. Amiel SA. It’s all in the name: what exactly is hypoglycemia? Diabetic Hypoglycemia 2013;5:15-18.
88. Plowman R, Graves N, Esquivel J, Roberts JA. An economic model to assess the cost and benefits of the routine use of silver alloy coated urinary catheters to reduce the risk of urinary tract infections in catheterized patients. J Hosp Infect 2001;48:33-42. http://dx.doi.org/10.1053/jhin.2001.0938
89. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014;103:373-81. http://dx.doi.org/10.1016/j.diabres.2013.12.052
90. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med 2013;125:33-46. http://dx.doi.org/10.3810/pgm.2013.05.2650
91. Grandy S, Fox KM, Hardy E. Prevalence and recurrence of urinary tract and genital infections among adults with and without type 2 diabetes mellitus in the general population: a longitudinal cohort study. J Diab Res Clin Met 2013;2:1. https://doi.org/10.7243/2050-0866-2-5
92. Stenlöf K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014;30:163-75. http://dx.doi.org/10.1185/03007995.2013.850066
93. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92. http://dx.doi.org/10.1007/s00125-013-3039-1
94. Inagaki N, Kondo K, Yoshinari T, Kuki H. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52-week open-label study. J Diabetes Investig 2015;6:210-18. http://dx.doi.org/10.1111/jdi.12266
95. Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015;38:355-64. http://dx.doi.org/10.2337/dc13-2762
96. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015;38:403-11. http://dx.doi.org/10.2337/dc14-1237
97. Davies M, Kushner P, Vijapurkar U, Meininger G. Incidence of genital mycotic infections decreases over time in older patients with type 2 diabetes mellitus treated with canagliflozin. J Gen Intern Med 2015;30:S61-2.
98. Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014;126:7-17. http://dx.doi.org/10.3810/pgm.2014.01.2720
99. Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014;30:1109-19. http://dx.doi.org/10.1185/03007995.2014.890925
100. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, doubleblind, placebo-controlled 102-week trial. BMC Med 2013;11:43. http://dx.doi.org/10.1186/1741-7015-11-43
101. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473-8.
102. Kaku K, Maegawa H, Tanizawa Y, Kiyosue A, Ide Y, Tokudome T, et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther 2014;5:415-33. http://dx.doi.org/10.1007/s13300-014-0086-7
103. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebocontrolled trial. Lancet 2010;375:2223-33. http://dx.doi.org/10.1016/S0140-6736(10)60407-2
104. Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 2015;38:365-72. http://dx.doi.org/10.2337/dc14-0666
105. Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38:376-83. http://dx.doi.org/10.2337/dc14-1142
106. Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf 2014;37:815-29. http://dx.doi.org/10.1007/s40264-014-0213-4
107. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al. Empagliflozin monotherapy improves glucose control in drug-naive patients with type 2 diabetes (type 2 diabetes). Diabetes 2013;62:A280.
108. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369-84. http://dx.doi.org/10.1016/S2213-8587(13)70208-0
109. DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384-93. [Erratum published in Diabetes Care 2015;38:1173.] http://dx.doi.org/10.2337/dc14-2364
110. Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC, EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37:1815-23. http://dx.doi.org/10.2337/dc13-3055
111. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ, EMPA-REG BASALTM trial investigators. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-48. http://dx.doi.org/10.1111/dom.12503
112. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC, EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013;36:3396-404. http://dx.doi.org/10.2337/dc12-2673
113. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ, EMPAREG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9. http://dx.doi.org/10.2337/dc13-2105
114. Haring HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Empagliflozin (EMPA) for >76 weeks as add-on to metformin plus sulfonylurea (SU) in patients with type 2 diabetes (type 2 diabetes). Diabetes 2014;63:A280.
115. Merker L, Haring HU, Christiansen AV, Roux F, Salsali A, Kim G, et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet. Med 2015;32:1555-67. https://doi.org/10.1111/dme.12814
116. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:691-700. http://dx.doi.org/10.1016/S2213-8587(14)70120-2
117. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG PIO™ trial investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147-58. http://dx.doi.org/10.1111/dom.12188
118. Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clin Ther 2015;37:1773-88.e1. http://dx.doi.org/10.1016/j.clinthera.2015.05.511
119. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22. https://doi.org/10.2337/dc11-0606
120. Gangal NS, Kelton C, Heaton PC. Urinary tract infection among the SGLT 2 Inhibitors: a meta-Analysis of 19 randomized controlled trials. Value Health 2015;18:A52. https://doi.org/10.1016/j.jval.2015.03.308
121. European Medicines Agency (EMA). Review of Diabetes Medicines Called SGLT2 Inhibitors Started. 2015. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f (accessed 4 September 2015).
122. US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA Warns that SGLT2 Inhibitors for Diabetes may Result in a Serious Condition of Too Much Acid in the Blood. 2015. URL: www.fda.gov/drugs/drugsafety/ucm446845.htm (accessed 4 September 2015).
123. Erondu N, Desai M, Ways K, Meininger G. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-6. http://dx.doi.org/10.2337/dc15-1251
124. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-42. https://doi.org/10.2337/dc15-1380
125. Srivali N, Thongprayoon C, Cheungpasitporn W, Ungprasert P. Acute pancreatitis in the use of canagliflozin: a rare side-effect of the novel therapy for type 2 diabetes mellitus. J Basic Clin Pharm 2015;6:101-2. http://dx.doi.org/10.4103/0976-0105.160753
126. Kaur A, Winters SJ. Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin. Endocrinol Diabetes Metab Case Rep 2015;150042. http://dx.doi.org/10.1530/EDM-15-0042
127. US Food and Drug Administration (FDA). MedWatch: The FDA Safety Information and Adverse Event Reporting Program. 2015. URL: www.fda.gov/Drugs/DrugSafety/ucm459579.htm (accessed 4 September 2015).
128. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metab Clin Exp 2014;63:1228-37. http://dx.doi.org/10.1016/j.metabol.2014.06.018
129. Janssen Research & Development LLC. CANVAS-CANagliflozin cardioVascular Assessment Study; 2015. URL: https://clinicaltrials.gov/ct2/show/NCT01032629 (accessed 4 September 2015).
130. AstraZeneca. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). 2015. URL: https://clinicaltrials.gov/ct2/show/NCT01730534 (accessed 4 September 2015).
131. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013;1:140-51. http://dx.doi.org/10.1016/S2213-8587(13)70050-0
132. US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA Revises Label of Diabetes Drug Canagliflozin (Invokana, Invokamet) to Include Updates on Bone Fracture Risk and New Information on Decreased Bone Mineral Density; 2015. URL: www.fda.gov/Drugs/DrugSafety/ucm461449.htm (accessed 27 September 2015).
133. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-71. https://doi.org/10.1038/ki.2013.356
134. Kwon H, US Food and Drug Administration (FDA). Canagliflozin: Clinical Efficacy and Safety. 2013. URL: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm336234.pdf (accessed August 2005).
135. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-52. http://dx.doi.org/10.1210/jc.2015-1884
136. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. http://dx.doi.org/10.1056/NEJMoa1504720
137. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol 2014;13:102. http://dx.doi.org/10.1186/1475-2840-13-102
138. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. https://doi. org/10.1136/bmj.317.7160.703
139. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. http://dx.doi.org/10.1056/NEJM200001203420301
140. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. http://dx.doi.org/10.1056/NEJMoa1307684
141. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. http://dx.doi.org/10.1056/NEJMoa1305889
142. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42. http://dx.doi.org/10.1056/NEJMoa1501352
143. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. http://dx.doi.org/10.1056/NEJMoa072761
144. Hirshberg B, Katz A. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective. Curr Diab Rep 2015;15:87. http://dx.doi.org/10.1007/s11892-015-0663-9
145. Indianapolis Business Journal. Analyst: Lilly’s Jardiance Diabetes Pill could be a 6 Billion-a-year Blockbuster. 2015. URL: www.ibj.com/blogs/12-the-dose/post/54957-analyst-lillys-jardiancediabetes-pill-could-be-a-6-billion-a-year-blockbuster (accessed 25 September 2015).
146. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006;67:235-40. http://dx.doi.org/10.1212/01.wnl.0000224760.22802.e8
147. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. URL: www.medicinescomplete.com (accessed 1 August 2015).
148. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000;40:49-57. https://doi.org/10.1177/00912700022008694
149. Saleem K, Yasin MA, Asrar A, Qamar S. Comparison of repaglinide with glibenclamide in the reduction of 13 HbA1C of type 2 diabetic patients. Pak J Med Health Sci 2011;5:23-6.
150. Shah ZH, Saleem K, Mahboob F, Jibran R. A comparative study of repaglinide and glibenclamide in type 2 diabetic patients. Pak J Med Health Sci 2011;5:476-9.
151. Jibran R, Suliman M, Qureshi F, Ahmed M. Safety and efficacy of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients. Pak J Med Sci 2006;22:385-90.
152. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003;25:472-84. https://doi.org/10.1016/S0149-2918(03)80090-5
153. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43:155-66. https://doi.org/10.1016/S0168-8227 (99)00002-9
154. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7. http://dx.doi.org/10.2337/dc06-0703
155. Chen Y, Ning G, Wang C, Gong Y, Patel S, Zhang C, et al. Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: a multinational, 24-week, randomized, clinical trial. J Diabetes Investig 2015;6:692-8. http://dx.doi.org/10.1111/jdi.12346
156. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-23. https://doi.org/10.1055/s-2007-970422
157. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-67. http://dx.doi.org/10.1111/j.1463-1326.2010.01350.x
158. Erem C, Ozbas HM, Nuhoglu I, Deger O, Civan N, Ersoz HO. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2014;122:295-302. http://dx.doi.org/10.1055/s-0034-1370989
159. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res 2009;41:905-9. http://dx.doi.org/10.1055/s-0029-1234042
160. Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, doubleblind, placebo-controlled study. Diabetes Obes Metab 2012;14:565-74. http://dx.doi.org/10.1111/j.1463-1326.2012.01590.x
161. Kikuchi M, Kaku K, Odawara M, Momomura S, Ishii R. Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks’ treatment, comparative study. Curr Med Res Opin 2012;28:1007-16. http://dx.doi.org/10.1185/03007995.2012.694361
162. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004;27:41-6. https://doi.org/10.2337/diacare.27.1.41
163. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002;25:517-23.
164. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013;42:332-45. http://dx.doi.org/10.1093/ije/dys222
165. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44. http://dx.doi.org/10.1002/sim.3767
166. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comp Graph Stat 1998;7:434-5.
167. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708. http://dx.doi.org/10.1007/s00125-012-2827-3
168. De Fine Olivarius N, Andreasen AH, Siersma V, Richelsen B, Beck-Nielsen H. Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus. Diabetologia 2006;49:2058-67. https://doi.org/10.1007/s00125-006-0328-y
169. Genuth S. Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on! Diabetes Care 2015;38:170-5. Diabetes Care 2015;38:e95. http://dx.doi.org/10.2337/dc15-0519
170. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013;56:973-84. http://dx.doi.org/10.1007/s00125-013-2856-6
171. Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, Canovatchel W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005;68:167-75. http://dx.doi.org/10.1016/j.diabres.2004.09.002
172. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995-1000. https://doi.org/10.2337/diacare.28.5.995
173. Del Prato S, Nauck M, Durán-Garcia S, Maffei L, Rohwedder K, Theuerkauf A, Parikh S. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015;17:581-90. http://dx.doi.org/10.1111/dom.12459
174. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. http://dx.doi.org/10.1056/NEJMoa066224
175. Bacon T, Willis M, Johansen P, Neslusan C. Time until insulin initiation for canagliflozin (CANA) versus dapagliflozin (DAPA) in dual and triple therapy for type 2 diabetes mellitus (T2DM) in Ireland. Value Health 2015;18:A55. https://doi.org/10.1016/j.jval.2015.03.324
176. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-69. https://doi.org/10.1111/j.1463-1326.2007.00839.x
177. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205. https://doi.org/10.1111/j.1463-1326.2006.00704.x
178. Canadian Agency for Drugs and Technologies in Health (CADTH). Second-and Third-Line Pharmacotherapy for Type 2 Diabetes. Update: CADTH Optimal Use Report, No. 3.1. 2013. URL: www.ncbi.nlm.nih.gov/pubmedhealth/PMH0061000 (accessed 7 September 2015).
179. National Institute for Health and Care Excellence (NICE). Exenatide Prolonged-release Suspension for Injection in Combination with Oral Antidiabetic Therapy for the Treatment of Type 2 Diabetes. TA248, 2012. URL: www.nice.org.uk/guidance/ta248 (accessed August 2015).
180. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50. http://dx.doi.org/10.1016/S0140-6736(08)61206-4
181. Hattersley AT, Thorens B. Type 2 diabetes, SGLT2 inhibitors, and glucose secretion. N Engl J Med 2015;373:974-6. http://dx.doi.org/10.1056/NEJMcibr1506573
182. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19:279-84. https://doi.org/10.1046/j.1464-5491.2002.00689.x
183. US Food and Drug Administration (FDA). NDA 202293 Dapagliflozin Tablets, 5 and 10 mg. FDA Briefing Document. 2011. URL: www.fda.gov/DOWNLOADS/ADVISORYCOMMITTEES/COMMITTEESMEETINGMATERIALS/DRUGS/ENDOCRINOLOGICANDMETABOLICDRUGSADVISORY COMMITTEE/UCM262994.PDF (accessed 2 October 2015).
184. Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K. Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘case study’. Diabetes Ther 2015;6:357-75. http://dx.doi.org/10.1007/s13300-015-0128-9
185. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association (ADA). Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30. http://dx.doi.org/10.1007/s00125-008-1157-y
186. Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53:1258-69. http://dx.doi.org/10.1007/s00125-010-1702-3
187. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013;15:906-14. http://dx.doi.org/10.1111/dom.12102
188. Shihara N, Kitaoka M, Inagaki N, Kadowaki T, Koumoto S, Satoh J, et al. Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: a comparative study. J Diabetes Investig 2011;2:391-8. http://dx.doi.org/10.1111/j.2040-1124.2011.00115.x
189. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007;57:455-60.
190. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007;24:1412-18. http://dx.doi.org/10.1111/j.1464-5491.2007.02279.x
191. Health and Social Care Information Centre. Quality and Outcomes Framework (QOF). 2015. URL: http://qof.hscic.gov.uk/(accessed 27 September 2015).
192. Neslusan C, Johansen P, Willis M, Martin S. A health economic analysis of the long-term benefits and associated cost offsets of canagliflozin monotherapy in the U.S. Diabetes 2013;62:A322.
193. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59. https://doi.org/10.1007/s00125-004-1527-z
194. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56:1925-33. http://dx.doi.org/10.1007/s00125-013-2940-y
195. Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med 2015;32:459-66. http://dx.doi.org/10.1111/dme.12647
196. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS study no. 65). Diabet Med 2003;20:442-50. https://doi.org/10.1046/j.1464-5491.2003.00972.x
197. Alva M, Gray A, Mihaylova B, Clarke P. The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ 2014;23:487-500. http://dx.doi.org/10.1002/hec.2930
198. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9. https://doi.org/10.1177/027298902400448902
199. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30. http://dx.doi.org/10.1002/hec.910
200. University College London. THIN Database. URL: www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database (accessed 2 December 2016).
201. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009;11:372-8. http://dx.doi.org/10.1111/j.1463-1326.2008.00976.x
202. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14(36). http://dx.doi.org/10.3310/hta14360
203. Department of Health (DH). Health Survey for England 2003. 2004. URL: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/publicationsandstatistics/publications/publicationsstatistics/dh_4098712 (accessed 1 October 2015).
204. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34. https://doi.org/10.1185/030079906X115757
205. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract 1997;44:49-60.
206. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting: a multicentre study. Nephrol Dial Transplant 2008;23:1982-9. http://dx.doi.org/10.1093/ndt/gfm870
207. Hammer M, Lammert M, Mejías SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90. http://dx.doi.org/10.3111/13696990903336597
208. Curtis L. Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent; 2014. URL: www.pssru.ac.uk/project-pages/unit-costs/2014/(accessed 21 September 2015).
209. Chen J, Alemao E, Yin D, Cook J. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes Obes Metab 2008;10:33-42. https://doi.org/10.1111/j.1463-1326.2008.00885.x
210. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):5-26. https://doi.org/10.1185/030079904X1980
211. National Institute for Health and Care Excellence (NICE). Obesity Prevention. CG43, December 2006. URL: www.nice.org.uk/guidance/cg43 (accessed 1 August 2015).
212. Diabetics With Eating Disorders (DWED). Diabetes and DKA in England’s Primary Care Trusts. 2010. URL: http://dwed.org.uk/sites/default/files/DwedReportDKAPCT.pdf (accessed 20 September 2015).
213. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995;311:1595-9. https://doi.org/10.1136/bmj.311.7020.1595
214. Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, Barber BL. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65. https://doi.org/10.1007/s11136-007-9226-0
215. National Institute for Health and Care Excellence (NICE). Infection: Prevention and Control of Healthcare-associated Infections in Primary and Community care. NICE guidelines [CG139]. 2012. URL: www.nice.org.uk/guidance/cg139/documents (accessed 21 September 2015).
216. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778-92. https://doi.org/10.1097/00005650-199806000-00002
217. Ackerman SJ, Rein AL, Blute M, Beusterien K, Sullivan EM, Tanio CP, et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Urology 2000;56:972-80. https://doi.org/10.1016/S0090-4295(00)00828-1
218. Ellis AK, Verma S. Quality of life in women with urinary tract infections: is benign disease a misnomer? J Am Board Fam Pract 2000;13:392-7. https://doi.org/10.3122/15572625-13-6-392
219. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008;11:1131-43. http://dx.doi.org/10.1111/j.1524-4733.2008.00352.x
220. Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women’s quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual Life Outcomes 2005;3:45. http://dx.doi.org/10.1186/1477-7525-3-45
221. Lamping DL, Constantinovici N, Roderick P, Normand C, Henderson L, Harris S, et al. Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study. Lancet 2000;356:1543-50. https://doi.org/10.1016/S0140-6736(00)03123-8
222. Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study. Diabet Med 2005;22:316-22. http://dx.doi.org/10.1111/j.1464-5491.2005.01421.x
223. Coppell KJ, Kataoka M, Williams SM, Chisholm AW, Vorgers SM, Mann JI. Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment-Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial. BMJ 2010;341:c3337. http://dx.doi.org/10.1136/bmj.c3337
224. National Institute for Health and Care Excellence (NICE). Obesity: Identification, Assessment and Management of Overweight and Obesity in ChIldren, Young People and Adults. NICE guidelines [CG189]. URL: www.nice.org.uk/guidance/cg189 (accessed 2 October 2015).
225. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597-602. https://doi.org/10.2337/diacare.27.11.2597
226. Yang W, Weng J. Early therapy for type 2 diabetes in China. Lancet Diabetes Endocrinol 2014;2:992-1002. http://dx.doi.org/10.1016/S2213-8587(14)70136-6
227. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013;1:28-34. http://dx.doi.org/10.1016/S2213-8587(13)70006-8
228. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-6. https://doi.org/10.2337/diacare.20.9.1353
229. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-32. https://doi.org/10.2337/diacare.27.5.1028
230. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010;33:501-6. http://dx.doi.org/10.2337/dc09-1749
231. Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, DeFronzo RA. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17:268-75. http://dx.doi.org/10.1111/dom.12417
232. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-14. http://dx.doi.org/10.1007/s00125-011-2204-7
233. Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long-and short-duration type 2 diabetes. Diabet Med 2015;32:1149-55. http://dx.doi.org/10.1111/dme.12722
234. Gillett M, Royle P, Snaith A, Scotland G, Poobalan A, Imamura M, et al. Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technol Assess 2012;16(33). http://dx.doi.org/10.3310/hta16330
235. Perri MG, Anton SD, Durning PE, Ketterson TU, Sydeman SJ, Berlant NE, et al. Adherence to exercise prescriptions: effects of prescribing moderate versus higher levels of intensity and frequency. Health Psychol 2002;21:452-8. https://doi.org/10.1037/0278-6133.21.5.452
236. Hansen D, Dendale P, Jonkers RA, Beelen M, Manders RJ, Corluy L, et al. Continuous low-to moderate-intensity exercise training is as effective as moderate-to high-intensity exercise training at lowering blood HbA(1c) in obese type 2 diabetes patients. Diabetologia 2009;52:1789-97. http://dx.doi.org/10.1007/s00125-009-1354-3
237. Yates T, Davies M, Gorely T, Bull F, Khunti K. Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. Diabetes Care 2009;32:1404-10. http://dx.doi.org/10.2337/dc09-0130
238. Hawley JA, Gibala MJ. Exercise intensity and insulin sensitivity: how low can you go? Diabetologia 2009;52:1709-13. http://dx.doi.org/10.1007/s00125-009-1425-5
239. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 2006;29:2518-27. https://doi.org/10.2337/dc06-1317
240. Praet SF, van Loon LJ. Exercise therapy in type 2 diabetes. Acta Diabetol 2009;46:263-78. http://dx.doi.org/10.1007/s00592-009-0129-0
241. Zanuso S, Jimenez A, Pugliese G, Corigliano G, Balducci S. Exercise for the management of type 2 diabetes: a review of the evidence. Acta Diabetol 2010;47:15-22. http://dx.doi.org/10.1007/s00592-009-0126-3
242. National Institute for Health and Care Excellence (NICE). Weight Management: Lifestyle Services for Overweight or Obese Adults. NICE guidelines [PH53]. 2014. URL: www.nice.org.uk/guidance/ph53 (accessed 2 October 2015).
243. Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical activity: a modelling study. PLOS Med 2009;6:e1000110. http://dx.doi.org/10.1371/journal.pmed.1000110
244. Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:186-94. http://dx.doi.org/10.1111/j.1463-1326.2009.01155.x
245. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481-6. http://dx.doi.org/10.2337/dc10-2415
246. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9. https://doi.org/10.1080/07315724.2003.10719316
247. Jacobs-vanderBruggen MA, van Baal PH, Hoogenveen RT, Feenstra TL, Briggs AH, Lawson K, et al. Cost-effectiveness of lifestyle modification in diabetic patients. Diabetes Care 2009;32:1453-8. http://dx.doi.org/10.2337/dc09-0363
248. Bailey CJ, Iqbal N, T’joen C, List JF. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012;14:951-9. http://dx.doi.org/10.1111/j.1463-1326.2012.01659.x
249. Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord 2013;13:58. http://dx.doi.org/10.1186/1472-6823-13-58
250. Blüher M, Schweizer A, Bader G, Foley JE. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. Vasc Health Risk Manag 2014;10:661-4. http://dx.doi.org/10.2147/VHRM.S73608
251. Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther 2012;29:889-99. http://dx.doi.org/10.1007/s12325-012-0055-3
252. Escudero Vilaplana B, Almodóvar Carretón MJ, Herrero Hernández S. [Dapagliflozin, a novel oral antidiabetic with an uncertain future.] Farm Hosp 2014;38:468-74. http://dx.doi.org/10.7399/fh.2014.38.6.7963
253. Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013;36:4015-21. http://dx.doi.org/10.2337/dc13-0663
254. Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, Barnett AH. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 2014;16:433-42. http://dx.doi.org/10.1111/dom.12239
255. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446-56. http://dx.doi.org/10.1111/j.1742-1241.2012.02911.x
256. Hussey EK, Kapur A, O’Connor-Semmes R, Tao W, Rafferty B, Polli JW, et al. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol 2013;14:25. http://dx.doi.org/10.1186/2050-6511-14-25
257. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat 2013;27:479-84. http://dx.doi.org/10.1016/j.jdiacomp.2013.04.012
258. Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther 2014;31:621-38. http://dx.doi.org/10.1007/s12325-014-0126-8
259. Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebocontrolled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014;13:65. http://dx.doi.org/10.1186/1475-2840-13-65
260. Lutz SZ, Staiger H, Fritsche A, Häring HU. Antihyperglycaemic therapies and cancer risk. Diab Vasc Dis Res 2014;11:371-89. http://dx.doi.org/10.1177/1479164114549553
261. Matthaei S. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus.] Dtsch Med Wochenschr 2014;139(Suppl 2):59-64. https://doi.org/10.1055/s-0033-1359992
262. Nauck M, del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin.] Dtsch Med Wochenschr 2013;138(Suppl 1):6-15. http://dx.doi.org/10.1055/s-0032-1305283
263. Orme M, Fenici P, Lomon ID, Wygant G, Townsend R, Roudaut M. A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetol Metab Syndr 2014;6:73. http://dx.doi.org/10.1186/1758-5996-6-73
264. Pafili K, Papanas N. Tofogliflozin: the road goes ever on. Expert Opin Pharmacother 2014;15:1197-201. http://dx.doi.org/10.1517/14656566.2014.916278
265. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2014;16:410-17. http://dx.doi.org/10.1111/dom.12233
266. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:2289-312. http://dx.doi.org/10.2165/11209910-000000000-00000
267. Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:807-24. http://dx.doi.org/10.1007/s40265-014-0225-5
268. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 2014;57:891-901. http://dx.doi.org/10.1007/s00125-014-3196-x
269. Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev 2013;29:347-56. https://doi.org/10.1002/dmrr.2403
270. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8. http://dx.doi.org/10.2337/dc11-1926
271. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA (1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8. http://dx.doi.org/10.2337/dc11-1693
272. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15:1154-60. http://dx.doi.org/10.1111/dom.12185
273. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59. http://dx.doi.org/10.1007/s40265-014-0337-y
274. Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin 2014;30:1219-30. https://doi.org/10.1185/03007995.2014.901943
275. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014;30:1245-55. http://dx.doi.org/10.1185/03007995.2014.912983
276. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, doubleblind, placebo-controlled, phase II study. Curr Med Res Opin 2014;30:1231-44. http://dx.doi.org/10.1185/03007995.2014.909390
277. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-38. https://doi.org/10.1111/j.1463-1326.2011.01434.x
278. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride.] Dtsch Med Wochenschr 2013;138(Suppl 1):16-26. http://dx.doi.org/10.1055/s-0032-1305277
279. Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 2014;5:267-83. http://dx.doi.org/10.1007/s13300-014-0072-0
280. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med 2014;126:16-34. http://dx.doi.org/10.3810/pgm.2014.05.2753
281. Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 2013;15:403-9. http://dx.doi.org/10.1111/dom.12038
282. Yang XP, Lai D, Zhong XY, Shen HP, Huang YL. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 2014;70:1149-58. http://dx.doi.org/10.1007/s00228-014-1730-x
283. Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther 2013;35:273-85.e7. http://dx.doi.org/10.1016/j.clinthera.2013.01.010
284. Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2014;30:204-21. https://doi.org/10.1002/dmrr.2479
285. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-11. https://doi.org/10.2337/diacare.23.11.1605
286. Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab 2012;14:1145-54. http://dx.doi.org/10.1111/dom.12011
287. Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-58. http://dx.doi.org/10.1185/03007995.2011.568059
288. Chou HS, Truitt KE, Moberly JB, Merante D, Choi Y, Mun Y, Pfützner A. A 26-week, placebo-and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:1000-9. http://dx.doi.org/10.1111/j.1463-1326.2012.01631.x
289. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87. http://dx.doi.org/10.2337/dc07-0627
290. Kamel AN, Cetinarslan B, Uysal AR, Baskal N, Corapcioglu D, Tonyukuk V. Efficacy of monotherapy with acarbose, glibenclamide, gliclazide, metformin or placebo in NIDDM patients. Diabetologia 1997;40:A138.
291. Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106-16. http://dx.doi.org/10.1016/j.diabres.2008.10.009
292. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-24. https://doi.org/10.2337/diacare.22.1.119
293. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001;24:11-15. https://doi.org/10.2337/diacare.24.1.11
294. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H, Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71. https://doi.org/10.1007/s00125-006-0416-z
295. Scherbaum WA, Göke B, German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002;34:589-95. http://dx.doi.org/10.1055/s-2002-35421